|Chemical and physical data|
|Molar mass||512.6 g/mol (free base) g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Almorexant (INN, codenamed ACT-078573) is an orexin antagonist, functioning as a competitive receptor antagonist of the OX1 and OX2 orexin receptors, which was being developed by the pharmaceutical companies Actelion and GSK for the treatment of insomnia. Development of the drug was abandoned in January 2011 due to undisclosed issues pertaining to Almorexant's safety profile.
Originally developed by Actelion, from 2007 almorexant was being reported as a potential blockbuster drug, as its novel mechanism of action (orexin receptor antagonism) was thought to produce better quality sleep and fewer side effects than the traditional benzodiazepines and Z-drugs which dominated the multibillion-dollar insomnia medication market.
In 2008, pharmaceutical giant GlaxoSmithKline bought the development and marketing rights for almorexant from Actelion for an initial payment of $147 million. The deal was worth a potential $3.2billion if the drug were to successfully complete clinical development and obtain FDA approval. GSK and Actelion continued to develop the drug together, and completed a Phase III clinical trial in November 2009.
Mechanism of action
Almorexant is a competitive, dual OX1 and OX2 receptor antagonist and selectively inhibits the functional consequences of OX1 and OX2 receptor activation, such as intracellular Ca2+ mobilization.
- GSK and Actelion discontinue clinical development of almorexant Archived 2011-07-04 at the Wayback Machine - GSK press release, 28 Jan 2011
- Sleeping Beautifully - CBS Business Network 24 Sep 2007
- Actelion Sells Glaxo Almorexant Sleep Medicine Rights - Bloomberg, 14 July 2008
- Actelion's top dollar deal leaves doubts, and little on the horizon - EP Vantage, 14 July 2008
- Almorexant in Adult Subjects With Chronic Primary Insomnia (RESTORA 1). ClinicalTrials.gov (February 3, 2010). Retrieved on May 6, 2010.
- Actelion and GSK Discontinue Clinical Development of Almorexant Archived 2011-03-03 at the Wayback Machine - Actelion press release, 28 Jan 2011